Castle Biosciences Q3 2025 Earnings Report

Castle Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.35
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Castle Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $71.06 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Castle Biosciences Announcement Details

• Quarter: Q3 2025
• Date: 11/3/2025
• Time: Before Market Opens
• Conference Call Date: Monday, November 3, 2025
• Conference Call Time: 4:30PM ET

Castle Biosciences (NASDAQ:CSTL) is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches. In addition to its melanoma assay, Castle Biosciences offers DecisionDx-SCC for cutaneous squamous cell carcinoma and DecisionDx-Merkel for Merkel cell carcinoma. These tests leverage RNA expression profiling to stratify patients according to their individual risk profiles, enabling clinicians to determine optimal treatment intensity and follow-up schedules.

Founded in 2014 and headquartered in Friendswood, Texas, Castle Biosciences has expanded its operations across the United States, collaborating with dermatologists, oncologists and pathologists to integrate its tests into routine clinical practice. The company went public in 2017 and has since pursued strategic partnerships with academic medical centers and commercial laboratories to broaden access to its diagnostic services. Castle Biosciences maintains a robust intellectual property portfolio to protect its assay methodologies and ongoing research initiatives.

Guided by an experienced management team, Castle Biosciences continues to advance its pipeline of dermatologic tests and explore applications in other oncology and immune-mediated disease settings. The company’s leadership emphasizes rigorous clinical validation, regulatory compliance and payer engagement to support reimbursement and drive adoption of its genomic tests. Through ongoing research collaborations and real-world evidence generation, Castle Biosciences aims to refine its testing platforms and extend the clinical utility of molecular diagnostics in dermatology and beyond.